Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.

Asamer, E, Szkandera, J, Gibiser, P, Lembeck, AL, Stojakovic, T, Kornprat, P, Lackner, C, Winder, T, Schlick, K, Stoger, H, Gerger, A, Pichler, M, Stotz, M.

https://www.ncbi.nlm.nih.gov/pubmed/30132196